Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection

Abstract

Patients with a history of depression who were not receiving antidepressants and active IDUs are more likely to fail treatment for genotype 2/3 HCV and will need additional support.

Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System

“…This rate is lower than other reports from tertiary medical centers, referral centers, and clinical trials, where SVR rates have been reported to range between 72% and 89%. [11][12][13][14][15][16]24 One potential reason for the low SVR rate was the high relapse rate (23.5%) in our patient population compared with rates reported by others. Relapse rates in the range of 10% to 15% for genotype 3 are generally reported in the literature.…”

“…For example, others have reported that patients with various degrees of liver disease, such as cirrhosis, advanced fibrosis, steatosis, and obesity, have lower SVR rates in genotype 3. [11][12][13][14][15][16]25 Age less than 45 years has been associated with improved SVR outcomes in genotype 3. 16 It is increasingly reported that HCV genotype 3 is more difficult to treat than previously thought and is associated with higher rates of complications than most other genotypes.…”

“…In an effort to the 72%-89% range are reported for genotype 3 HCV patients treated with PegINF and ribavirin. [11][12][13][14][15][16][17][18] However, these SVR results are from clinical trials or from patients treated at tertiary medical centers, university hospitals, and referral centers. [11][12][13][14][15][16][17][18] There is little information confirming these rates of SVR response in population-based studies.…”

Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome

“…It seems that cannabis receptor stimulation is associated with lower response to IFN treatment [80]. Moreover, it has been recently reported that patients with a history of depression who were not receiving antidepressants and active intravenous drug users are more likely to fail treatment for HCV genotype 2 or 3 and will need additional support [81].…”

Depression and pegylated interferon-based hepatitis C treatment

“…An observational study of 20 HCV genotype 2 or 3 patients demonstrated that patients with prior depression who were not on an antidepressant at the beginning of HCV therapy were more likely to drop out and achieved a lower SVR than HCV patients on antidepressants at the beginning of treatment. 58 Selective serotonin re-uptake inhibitors (SSRIs) have been shown to be effective in treating depression in IFN-treated patients. 59 In a study of 15 patients treated with citalopram, 87% responded well to the medication with no change in liver function tests when 10-40 mg/day of the drug was used.…”